復旦張江(688505.SH):奧貝膽酸片用於治療原發性膽汁性膽管炎藥品上市申請獲得受理
格隆匯10月31日丨復旦張江(688505.SH)公佈,公司全資子公司泰州復旦張江藥業有限公司於近日收到國家藥品監督管理局下發的關於奧貝膽酸片(規格:5mg、10mg)(簡稱“該藥品”)用於治療原發性膽汁性膽管炎(PBC)的境內生產藥品註冊上市許可申請的《受理通知書》,該藥品屬於法尼酯
X 受體(Farnesoid X receptor,FXR)激動劑,FXR
是一種在肝臟和腸道中高水平表達的核受體,在膽酸代謝調節中起關鍵性作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.